PDCD1 and colorectal carcinoma: Pembrolizumab and nivolumab, the primary PDCD1 inhibitors, have gained the Food and Drug Administration (FDA) approval for the CRC patients with high microsatellite instability (MSI-H) (Ganesh et al., 2019).